Quarterly Gain Still Eludes Dow Despite Triple-Digit Lead

All three major indexes are eyeing daily, weekly, and monthly wins

Digital Content Manager
Mar 31, 2023 at 11:57 AM
facebook X logo linkedin

The Dow Jones Industrial Average (DJI) is boasting a triple-digit lead this afternoon, as investors unpack this morning's flood of inflation data. Unlike the S&P 500 Index (SPX) and Nasdaq Composite Index (IXIC), the blue-chip benchmark is still eyeing a quarterly loss, though all three remain on track for weekly and monthly wins. The tech sector led much of this month's gains, with a strong performance from chip stocks. The Cboe Volatility Index (VIX) is eyeing a losing quarter, week, and month, as well as its sixth-straight daily loss.

Continue reading for more on today's market, including: 

  • These 2 Trump-linked stocks are moving higher.
  • Analyst downgrades Generac stock on risk reward.
  • Plus, options bulls blast UBS stock; quarterly win boosts YMAB; and biotech stock extends pullback.

MMC Stats 331

Options bulls are blasting UBS Group AG (NYSE:UBS) today, with 52,000 calls across the tape so far today -- 27 times the intraday average volume -- compared to 1,180 puts. The April 35 and 30 calls are the most popular contacts, with positions being opened at both. UBS is up 3.2% at $21.16 at last check, amid news that Sergio Ermotti will return as CEO for the Credit Suisse (CS) takeover. The security is eyeing its first close above the 40-day moving average in over three weeks, and sports a 13.2% year-to-date lead.

UBS 40 Day

Y-mAbs Therapeutics Inc (NASDAQ:YMAB) is one of the best stocks on the Nasdaq today, last seen up 69.6% to trade at $5.58. The company yesterday reported a surprise fourth-quarter profit of 3 cents per share as well as a revenue beat, with shares brushing off Canaccord Genuity's price-target cut to $18 from $20. YMAB is trading at its highest level since October, and has added 9% so far in 2023.

The shares of Annovis Bio Inc(NYSE:ANVS) were last seen at the bottom of the New York Stock Exchange (NYSE), down 20.5% at $15.99. The company today received the interim analysis for sample size re-estimation for its phase 3 clinical trial of its treatment for early Parkinson's disease. The $14.50 region looks poised to contain this pullback, as ANVS continues to cool from this week's rally to its highest level since September. Year-over-year, the equity is up 19.9%.


Target Effortless Triple-Digit Gains Every Sunday Evening For Life!

This is your chance to triple your profit potential on Sunday evenings, without spending all your free time watching the market.

On Sundays, as a Weekend Plus subscriber, you’ll get up to 6 trades every Sunday, each targeting gains of 200% or more.

Start targeting gains like the ones our subscribers have seen recently, including:

213.3% GAIN on AutoNation calls
100.0% GAIN on Monster Beverage calls
100.4% GAIN on Walgreens Boots Alliance puts
100.4% GAIN on ON Semiconductor calls
257.7% GAIN on Dell calls

101.0% GAIN on Apollo Global Management calls
103.6% GAIN on JP Morgan  Chase calls
105.3% GAIN on DraftKings calls
101.3% GAIN on Airbnb calls
203.0% GAIN on Shopify calls
102.0% GAIN on Cboe Global Markets calls
100.9% GAIN on Boeing calls
102.1% GAIN on Microsoft puts
102.3% GAIN on First Solar calls
101.5% GAIN on PulteGroup calls
101.0% GAIN on Apple calls
209.4% GAIN on NXP Semiconductors calls
100.8% GAIN on Uber Technologies calls
100.4% GAIN on Academy Sports and Outdoors puts
102.2% GAIN on Trade Desk calls
100.8% GAIN on DoorDash calls
100.0% GAIN on Camping World Holdings puts
100.0% GAIN on Cboe Global Markets calls
100.2% GAIN on C3.ai calls
238.5% GAIN on Oracle calls



Rainmaker Ads CGI